LEL Lilly(Eli)

 
TIDMLEL 
 
Date: June 12, 2012 
 
For Release: Immediately 
 
Refer to: (317) 276-5795 - Mark Taylor (Lilly Corporate) 
 
86-10-59042059 - Connie Li (Lilly China) 
 
86-13906294927-Cao Zhen (Novast) 
 
 Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve 
         Chinese Patients with High-Quality Branded Generic Medicines 
 
         Lilly will increase equity position in Novast by $20 million 
 
    Novast will set up a platform to supply Lilly-branded generic medicines 
 
INDIANAPOLIS, IN and NANTONG, CHINA - In support of its commitment to maximize 
growth opportunities in China, Eli Lilly and Company (NYSE:LLY) today announced 
an increase of its network of manufacturing capabilities in this key emerging 
market country through an expanded collaboration with Novast Laboratories, LTD. 
Novast, a generic and specialty pharmaceutical company based in Nantong, China, 
has established high-quality systems and manufacturing facilities for the 
global and domestic Chinese markets. Lilly expects its expanded collaboration 
with Novast to greatly enhance its efforts to build a portfolio of Lilly 
branded generic medicines in China. The collaboration may also ultimately 
result in Novast providing local and regional manufacturing capabilities for 
Lilly's own pipeline of potential new medicines in development. 
 
As part of the agreement, Lilly will increase its equity position in Novast by 
$20 million. Lilly made an initial equity investment in Novast several years 
ago through the Lilly venture capital unit, Lilly Asian Ventures. Novast has 
committed to set up a platform to support Lilly branded generic products and 
increase the manufacturing capacity at its Nantong site over the next several 
years, with Lilly providing technical support to enhance quality standards. The 
additional capacity will support the collaboration, but will not be solely 
dedicated to Lilly products. The two companies have selected an initial list of 
medicines across multiple therapeutic areas that will be manufactured by Novast 
once the facilities are operational. Additional terms of the agreement were not 
disclosed. 
 
"We are excited to expand our collaboration with Novast. As we develop a 
platform of high-quality Lilly branded generic medicines in China, we are 
supporting the Chinese governments' current 5-year plan, which calls for 
significant improvement in the quality of medicines in the pharmaceutical 
industry," said Jacques Tapiero, Lilly senior vice president and president of 
Emerging Markets. "In Lilly's emerging markets business, we are focused on 
providing patients with innovative medicines from our own pipeline, as well as 
select Lilly branded generic medicines that meet our quality standards. The 
additional manufacturing capabilities provided by Novast will allow us to 
better deliver on that strategy." 
 
"In China, Lilly is building for the future by investing across our value 
chain," said Eric Baclet, president and general manager of Lilly China. "We 
have made significant investments in research and development, increased our 
commercial presence to better serve patients and healthcare providers, and 
expanded our manufacturing capabilities both at Lilly owned sites and through 
partner companies such as Novast. We are committed to help meet the medical 
needs of the Chinese people by providing innovative medicines of the highest 
quality." 
 
"This long term strategic partnership will combine Lilly's expertise in 
innovation, commercialization and operations with Novast's strengths in product 
development and quality manufacturing," said Dr. Guohua Zhang, president and 
CEO of Novast Laboratories. "We are committed to helping Lilly bring 
high-quality medicines to patients in China and potentially other countries. We 
are looking forward to working together constructively and cooperatively in the 
years ahead to achieve our business objectives." 
 
"At Novast, quality is our main focus. In every market we serve, and every 
regulatory body we work with, we feel that we have a moral responsibility 
towards the consumer. That is the overriding quality benchmark we employ in 
producing our products," said Prasad Pinnamaraju, senior vice president and 
chief operating officer of Novast Holdings, LTD. 
 
About Eli Lilly and Company 
 
Lilly, a leading innovation-driven corporation, is developing a growing 
portfolio of pharmaceutical products by applying the latest research from its 
own worldwide laboratories and from collaborations with eminent scientific 
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - 
through medicines and information - for some of the world's most urgent medical 
needs. Additional information about Lilly is available at www.lilly.com. C-LLY 
 
About Novast Laboratories LTD. 
 
Novast Laboratories, LTD., a subsidiary of Novast Holdings, LTD., is a 
pharmaceutical company based in Nantong, Jiangsu Province, China with a strong 
focus on design and development of quality finished products for the worldwide 
markets. Our strategy has been to establish collaborations with pharmaceutical, 
biotechnology, and generic companies to develop and commercialize products. We 
provide research solutions and product development services utilizing our 
extensive expertise and experience in product development and novel drug 
delivery systems. 
 
This press release contains forward-looking statements that are based on Lilly 
and Novast management's current expectations, but actual results may differ 
materially due to various factors. There are significant risks and 
uncertainties in pharmaceutical research and development. There can be no 
guarantees that manufacturing facilities and products will receive the 
necessary regulatory approvals, that products will prove to be commercially 
successful, or that Lilly will achieve the benefits expected from its 
collaboration with and investment in Novast, the planned facilities, or its 
product portfolio in China.. For additional information about the factors that 
affect the Lilly's business, please see the company's latest Form 10-Q and Form 
10-K filed with the U.S. Securities and Exchange Commission. The companies 
undertake no duty to update forward-looking statements. 
 
                                     # # # 
 
 
 
Novast Laboratories, Ltd. Eli Lilly and Company 
 
1 Guangxing Road Lilly Corporate Center 
 
Export Processing Zone, NETDA Indianapolis, Indiana 46285 
 
Nantong, China U.S.A. 
 
www.lilly.com 
 
 
 
 
 
 
 
 
 
 
 
 
END 
 

Lilly(Eli) (LSE:LEL)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025

Lilly(Eli) (LSE:LEL)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025